Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Revenue of Abilify globally by region 2011-2016

Worldwide revenue of Abilify from 2011 to 2016, by region (in million U.S. dollars)

by Matej Mikulic, last edited Feb 26, 2018
Revenue of Abilify globally by region 2011-2016 This statistic displays the global revenue of Abilify from Bristol-Myers Squibb by region from 2011 to 2016. In the United States alone, BMS generated a revenue of 2.1 billion U.S. dollars with Abilify in 2012. In 2016, due to patent expiration, Abilify generated revenues only outside the United States. Abilify is an antipsychotic agent that is used to treat various conditions such as schizophrenia, bipolar mania disorder, and major depressive disorder.
Show more

Worldwide revenue of Abilify from 2011 to 2016, by region (in million U.S. dollars)

U.S.Non-U.S.
---
---
---
---
---
---
U.S.Non-U.S.
---
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Matej Mikulic, last edited Feb 26, 2018
This statistic displays the global revenue of Abilify from Bristol-Myers Squibb by region from 2011 to 2016. In the United States alone, BMS generated a revenue of 2.1 billion U.S. dollars with Abilify in 2012. In 2016, due to patent expiration, Abilify generated revenues only outside the United States. Abilify is an antipsychotic agent that is used to treat various conditions such as schizophrenia, bipolar mania disorder, and major depressive disorder.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Pharmaceutical brands: Abilify (BMS/Otsuka)
Pharmaceutical brands: Abilify (BMS/Otsuka)

All Information
in one Presentation

Pharmaceutical brands: Abilify (BMS/Otsuka)

Everything On "Pharmaceutical brands: Abilify (BMS/Otsuka)" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical brands: Abilify (BMS/Otsuka)"
  • Overview
  • Drug prices and consumer behavior
  • Advertising expenditures
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.